Natalie Vokes, MD

NEADORA data highlights why early NGS guides resectable EGFR lung cancer care, favoring perioperative osimertinib and avoiding checkpoint inhibitors.

Experts explain how adjuvant osimertinib changes post-surgery EGFR lung cancer care, from rapid testing to real-world adherence.